UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000004474 |
|---|---|
| Receipt number | R000005175 |
| Scientific Title | KOBE Study of Pioglitazone Effective in Preventing Restenosis after Endovascular Therapy |
| Date of disclosure of the study information | 2010/11/01 |
| Last modified on | 2011/07/29 17:51:32 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
KOBE Study of Pioglitazone Effective in Preventing Restenosis after Endovascular Therapy
Acronym
KOBE-SPEED
Scientific Title
KOBE Study of Pioglitazone Effective in Preventing Restenosis after Endovascular Therapy
Scientific Title:Acronym
KOBE-SPEED
Region
| Japan |
Condition
Condition
Femoropopliteal artery lesion area (Rutherford 1 category 4) in type 2 diabetes complicated by a chronic arteriosclerosis obliterans
Classification by specialty
| Cardiology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To examine whether pioglitazone suppressed the development of restenosis after endovascular treatment(EVT: Endovascular Therapy) in patients with chronic obstructive atherosclerosis in type 2 diabetes mellitus.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Explanatory
Developmental phase
Assessment
Primary outcomes
After six months of treatment before and IVUS neointimal thickness by the amount of quantitative assessment.
Key secondary outcomes
1. Patency rate
2. Ankle Brachial Pressure Index (ABI)
3. Rutherford classification (1-4) Change in
4. All-cause mortality and cardiovascular events(TIA, including ischemic stroke, hemorrhagic stroke, myocardial infarction and other vascular accident)
5. Lower limb vascular event
Anputeshon (minor or major), move to bypass surgery, revascularization,
Stent thrombosis
6. Stent breakage rate
7. Angiographic restenosis
8. Angiographic Late Loss
9. Safety: edema, hypoglycemia, and others
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Blinding
Open -but assessor(s) are blinded
Control
Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Medicine |
Interventions/Control_1
Pioglitazone treatment groups: pioglitazone 15mg orally once daily after breakfast.
Aiming HbA1C6.5% less than the oral hypoglycemic drug dosage may be adjusted.
If you get side effects, the physician's discretion, lose weight or stop.
Interventions/Control_2
Pioglitazone untreated group: standard care(SU drugs, Alpha-glucosidase inhibitor, Gurinido drugs, Biguanide drugs), the aim HbA1C6.5% less than the oral hypoglycemic drug dosage may be adjusted.
If you get side effects, the physician's discretion, lose weight or stop.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1. Patients diagnosed with diabetes type 2
2. Femoropopliteal artery lesion area (Rutherford 1 - 4 categories) patients having chronic obstructive atherosclerosis.
However, acute (7 days), subacute (less than one month) is to exclude patients with limb ischemia.
3. Normal proximal portion , an average diameter of the target vessel distal vessel diameter of 4-6mm blood vessels in the average visual Target.
4. Stenosis or occlusion in the superficial femoral artery angiography new , TASKII Category A or B or C corresponding to the lesion. From the deep femoral artery bifurcation lesions in the distal superficial femoral artery and more than 1cm, 3cm from the patella to target those that exist between more proximal.
5. Run-off arteries below the knee and one or more, flow limiting stenosis, if you can not. In addition, patients with lesions on both sides of a merger, the aorta - a target for patients with iliac artery disease complications. However, endovascular treatment of bilateral lesions in patients with 30 days to make the treatment of each limb at intervals of 45 days.
6. Lower extremity arterial (BK:Below knee), iliac artery (Iliac Artery) with simultaneous treatment possible.
7. A target for occlusion
Key exclusion criteria
1. Patients with Congestive Heart Failure
2. Creatinine or 2mg/dL
3. Patients on hemodialysis
4. Leukopenia drug ingredients for research hepatic dysfunction, severe side effects such as renal dysfunction,
Patients with a history of hypersensitivity
5. Patients are pregnant or potentially pregnant women
6. Subacute patients with acute limb ischemia
7. Insulin-treated patients
(Eg, insulin administration was started during the study will continue to study)
8. Patients with a history of adverse reactions to thiazolidinediones
9. Patients with severe liver dysfunction in renal function
10. The patient will be excluded from the safety of thiazolidinediones in terms of
11. In addition, at the discretion of the attending physician considered patient inappropriate for study
Target sample size
50
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Toshiro Shinke |
Organization
Department of Internal Medicine, Kobe University Graduate School of Medicine
Division name
Division of Cardiovascular Medicine
Zip code
Address
7-5-1 Kusunoki-cho, Chuo-ku, Kobe
TEL
078-382-5846
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Toshiro Shinke |
Organization
Department of Internal Medicine, Kobe University Graduate School of Medicine
Division name
Division of Cardiovascular Medicine
Zip code
Address
7-5-1 Kusunoki-cho, Chuo-ku, Kobe
TEL
078-382-5846
Homepage URL
shinke@med.kobe-u.ac.jp
Sponsor or person
Institute
Division of Cardiovascular Medicine , Department of Internal Medicine,
Kobe University Graduate School of Medicine
Institute
Department
Personal name
Funding Source
Organization
Boston Scientific Corporation
Johnson & Johnson K.K.
Takeda Pharmaceutical Company
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2010 | Year | 11 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2010 | Year | 10 | Month | 04 | Day |
Date of IRB
Anticipated trial start date
| 2010 | Year | 10 | Month | 01 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2010 | Year | 10 | Month | 28 | Day |
Last modified on
| 2011 | Year | 07 | Month | 29 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005175
